1 2 3 4 5

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics . 27(3):89-100, March 2017.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

Lubomirov, Rubin; Arab-Alameddine, Mona; Rotger, Margalida; More

Pharmacogenetics and Genomics . 23(1):9-18, January 2013.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202

Verma, Anurag; Bradford, Yuki; Verma, Shefali S.; More

Pharmacogenetics and Genomics . 27(3):101-111, March 2017.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics . 26(2):66-73, February 2016.

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

Lorés-Motta, Laura; van Asten, Freekje; Muether, Philipp S.; More

Pharmacogenetics and Genomics . 26(1):20-27, January 2016.

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)

Lewis, Lionel D.; Miller, Antonius A.; Owzar, Kouros; More

Pharmacogenetics and Genomics . 23(1):29-33, January 2013.

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections

Hamadeh, Issam S.; Klinker, Kenneth P.; Borgert, Samuel J.; More

Pharmacogenetics and Genomics . 27(5):190-196, May 2017.

The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol...

Nakagawa, Takehiro; Kajiwara, Ayami; Saruwatari, Junji; More

Pharmacogenetics and Genomics . 23(1):34-37, January 2013.

Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine

Harris, Michael; Bhuvaneshwar, Krithika; Natarajan, Thanemozhi; More

Pharmacogenetics and Genomics . 24(2):81-93, February 2014.

Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response

Backman, Joshua D.; O’Connell, Jeffrey R.; Tanner, Keith; More

Pharmacogenetics and Genomics . 27(4):159-163, April 2017.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics . 26(1):28-39, January 2016.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

Lewis, Joshua P.; Horenstein, Richard B.; Ryan, Kathleen; More

Pharmacogenetics and Genomics . 23(1):1-8, January 2013.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics . 26(8):397-401, August 2016.

The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β1 adrenergic receptor antagonist esmolol in healthy individuals

Muszkat, Mordechai; Hoofien, Assaf; Orlanski-Meyer, Esther; More

Pharmacogenetics and Genomics . 23(1):25-28, January 2013.

1 2 3 4 5